New Zealand has the world's highest rates of serious illness caused by RSV, with 2000 children under five admitted to ...

ACIP is recommending that adults aged 50 to 59 years who are at increased risk for severe RSV disease receive a single dose of an RSV vaccine.

EPS estimates, maintains 2025 guidance, and targets $5.7 billion in cost savings through automation and R&D streamlining.

Vulnerable Australians aged 50-59 will be able to receive a vaccine for respiratory syncytial virus (RSV).

We recently published a list of Billionaire Ken Fisher’s 10 Healthcare Stock Picks with Massive Upside Potential. In this ...

Pfizer (NYSE:PFE) is a global pharmaceutical giant that has long been a cornerstone of medical innovation and today boasts a ...

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for ...

Kennedy Jr., a longtime anti-vaccine activist. HealthDay News — A panel of federal health experts recommended expanded vaccine options for several diseases, including respiratory syncytial virus (RSV) ...

Victorian babies will be safer from Respiratory Syncytial Virus (RSV) this winter, with a long-acting immunisation available free for eligible families through September 30.

"Who We Are." ETF.com. "SPY – SPDR S&P 500 ETF Trust." Pfizer. "U.S. FDA Approves Pfizer's RSV Vaccine ABRYSVO for Adults Aged 18 to 59 at Increased Risk for Disease." Pfizer. "U.S. FDA Approves ...

Eligible infants aged up to two years who are vulnerable to severe RSV disease will be protected thanks to a dedicated catch-up program. The state-based program complements the Commonwealth maternal ...